Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

6.6K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
6.6K
Cancer Therapies02:49

Cancer Therapies

9.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.7K
Cancer Vaccines01:30

Cancer Vaccines

880
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
880

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Second-line oxaliplatin reintroduction or paclitaxel-ramucirumab in metastatic gastroesophageal cancer: a population-based study.

Therapeutic advances in medical oncology·2026
Same author

Imaging strategies for follow-up during adjuvant nivolumab in esophageal cancer: A multicenter retrospective cohort study.

PloS one·2026
Same author

Adenocarcinoma of the small intestine cohort: prospectively collecting real-world data to improve care and quality of life for patients with a rare cancer.

Acta oncologica (Stockholm, Sweden)·2026
Same author

A trophoblast glycoprotein specific 5T4-Vδ2 bispecific T cell engager recruits Vγ9Vδ2-T cells for tumor-selective cytotoxicity across solid malignancies.

Clinical immunology (Orlando, Fla.)·2026
Same author

The intricate relationship between cytokines and galectins in immune modulation.

Cytokine & growth factor reviews·2026
Same author

Regulatory grammar in human promoters uncovered by MPRA-based deep learning.

Nature·2026

Related Experiment Video

Updated: Dec 28, 2025

Combination Radiotherapy in an Orthotopic Mouse Brain Tumor Model
08:02

Combination Radiotherapy in an Orthotopic Mouse Brain Tumor Model

Published on: March 6, 2012

16.8K

Combining Radiation Therapy With Interferons: Back to the Future.

Ruben S A Goedegebuure1, Christian Vonk2, Laura P Kooij2

  • 1Amsterdam UMC, location VUmc, Medical Oncology, Cancer Center Amsterdam, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands.

International Journal of Radiation Oncology, Biology, Physics
|February 19, 2020
PubMed
Summary
This summary is machine-generated.

Combining radiation therapy with interferon (IFN) treatments shows promise, but clinical trial results are mixed. Further research is needed to optimize this approach and manage potential toxicities for better cancer treatment outcomes.

More Related Videos

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.7K
Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation
07:20

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Published on: January 14, 2011

15.1K

Related Experiment Videos

Last Updated: Dec 28, 2025

Combination Radiotherapy in an Orthotopic Mouse Brain Tumor Model
08:02

Combination Radiotherapy in an Orthotopic Mouse Brain Tumor Model

Published on: March 6, 2012

16.8K
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.7K
Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation
07:20

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Published on: January 14, 2011

15.1K

Area of Science:

  • Oncology
  • Immunology
  • Radiotherapy

Background:

  • Radiation therapy can stimulate an intratumoral type I interferon (IFN) response, enhancing treatment efficacy.
  • Preclinical studies suggest interferons (IFNs) possess radiosensitizing properties, prompting interest in combination therapies.

Purpose of the Study:

  • To review the existing literature on combining radiation therapy with IFN-based treatments, focusing on IFN-α and IFN-β.
  • To evaluate the opportunities and challenges associated with this combination therapy approach.

Main Methods:

  • Systematic review of preclinical studies and clinical trials investigating radiation therapy combined with interferons.
  • Analysis of treatment outcomes, toxicity profiles, and unexplored aspects of the combination therapy.

Main Results:

  • Clinical trials combining radiation therapy with interferons have yielded diverse and challenging-to-interpret outcomes.
  • Increased severe toxicity (grade ≥3) has often led to negative recommendations, despite potential benefits.

Conclusions:

  • The mixed results and toxicity concerns regarding radiation therapy and interferon combinations may be premature.
  • Further research is required to address knowledge gaps and optimize the use of this combinatorial approach for cancer treatment.